Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Acquired by Virtus ETF Advisers LLC

Virtus ETF Advisers LLC increased its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 47.7% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 5,242 shares of the company’s stock after buying an additional 1,692 shares during the quarter. Virtus ETF Advisers LLC’s holdings in Intellia Therapeutics were worth $61,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Barclays PLC boosted its holdings in Intellia Therapeutics by 17.7% in the third quarter. Barclays PLC now owns 292,795 shares of the company’s stock valued at $6,017,000 after purchasing an additional 44,022 shares during the last quarter. Virtu Financial LLC purchased a new position in Intellia Therapeutics in the third quarter valued at about $417,000. Franklin Resources Inc. boosted its holdings in Intellia Therapeutics by 10.3% in the third quarter. Franklin Resources Inc. now owns 16,405 shares of the company’s stock valued at $320,000 after purchasing an additional 1,538 shares during the last quarter. Green Alpha Advisors LLC purchased a new position in Intellia Therapeutics in the fourth quarter valued at about $138,000. Finally, AdvisorNet Financial Inc boosted its holdings in Intellia Therapeutics by 96.4% in the fourth quarter. AdvisorNet Financial Inc now owns 10,085 shares of the company’s stock valued at $118,000 after purchasing an additional 4,950 shares during the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

Wall Street Analysts Forecast Growth

NTLA has been the subject of a number of analyst reports. Barclays reduced their price target on Intellia Therapeutics from $55.00 to $26.00 and set an “overweight” rating for the company in a report on Friday, February 28th. The Goldman Sachs Group reaffirmed a “sell” rating and set a $9.00 target price on shares of Intellia Therapeutics in a report on Friday, February 28th. Wedbush reaffirmed a “neutral” rating and set a $10.00 target price (down previously from $14.00) on shares of Intellia Therapeutics in a report on Friday, January 10th. StockNews.com raised Intellia Therapeutics to a “sell” rating in a report on Monday, March 3rd. Finally, BMO Capital Markets reduced their target price on Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating on the stock in a report on Friday, January 10th. Two analysts have rated the stock with a sell rating, six have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $36.68.

Intellia Therapeutics Price Performance

Shares of Intellia Therapeutics stock opened at $8.48 on Tuesday. Intellia Therapeutics, Inc. has a 1-year low of $5.90 and a 1-year high of $28.18. The company has a market capitalization of $877.82 million, a P/E ratio of -1.56 and a beta of 2.23. The business’s fifty day moving average price is $8.59 and its two-hundred day moving average price is $11.70.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.